Skip to content

The efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with intensity-modulated radiation therapy (IMRT) and targeted immunotherapy for CNLC stage IIIa primary hepatocellular carcinoma: a prospective single arm real-world study

The efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with intensity-modulated radiation therapy (IMRT) and targeted immunotherapy for CNLC stage IIIa primary hepatocellular carcinoma: a prospective single arm real-world study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101362
Enrollment
Unknown
Registered
2025-04-24
Start date
2025-04-30
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer with portal vein thrombosis (CNLC stage IIIa)

Interventions

Radiotherapy combined with HAIC treatment group:None

Sponsors

Jiangjin Central Hospital of Chongqing
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Meets the diagnostic criteria of the "Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition)", which includes enhanced MRI or CT scans of the upper abdomen, and conforms to the "fast in and fast out" enhancement features or liver biopsy for clear diagnosis; 2.Imaging examination confirmed the presence of portal vein thrombosis, consistent with CNLC stage IIIa, and after discussion by a multidisciplinary liver cancer diagnosis and treatment team, it was determined to be unresectable liver cancer; 3.The Child Pugh classification of liver function is A, B, and liver function can significantly improve after liver protection treatment. The liver function reserve test (indocyanine green method) meets the requirements of interventional therapy and radiation therapy; 4.The PS score for the patient's physical condition is 0-1 points; 5.The patient (or family) is fully aware of the treatment plan, risks, and potential risks, and signs an informed consent form;

Exclusion criteria

Exclusion criteria: 1.Patients with extensive and multiple metastases of liver cancer; 2.Child Pugh C liver function, large amount of ascites, severe jaundice, and severe bleeding tendency, which cannot be relieved after treatment; 3.Poor overall condition or cachexia; 4.There are contraindications for chemotherapy and/or radiotherapy, and there is no improvement after treatment; 5.Previously received other treatment plans;

Design outcomes

Primary

MeasureTime frame
objective response rate;overall survival;

Countries

China

Contacts

Public ContactHaoyang Tan

Jiangjin Central Hospital of Chongqing

595290707@qq.com+86 13609454209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026